Clinical Trial Finds CorMatrix ECM® Technology Does Not Increase Incidence of Postoperative Cardiac Tamponade or Graft Closure
11:43 EST 18 Jan 2013 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
CorMatrix® Cardiovascular, Inc., (www.cormatrix.com)
a leading medical device developer, today announced preliminary results
of its New Onset Post-Operative Atrial Fibrillation Clinical Trial. The
randomized, prospective trial ...
Other Sources for this Article
For CorMatrix® Cardiovascular, Inc.
Cookerly Public
Relations
Mike Mullet, 404-816-2037
mike@cookerly.com
More From BioPortfolio on "Clinical Trial Finds CorMatrix ECM® Technology Does Not Increase Incidence of Postoperative Cardiac Tamponade or Graft Closure"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
